Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population

We investigated the clinicopathological characteristics and survival of breast cancer lung metastases (BCLM) patients at initial diagnosis of metastatic breast cancer (MBC) in the Han population.
Nội dung trích xuất từ tài liệu:
Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han populationLinetal. BMC Cancer (2021) 21:1330https://doi.org/10.1186/s12885-021-09038-2 RESEARCH Open AccessClinicopathological characteristicsandsurvival outcomes inpatientswithsynchronous lung metastases uponinitialmetastatic breast cancer diagnosis inHanpopulationShaoyanLin, HongnanMo, YiqunLi, XiuwenGuan, YimengChen, ZijingWangand BingheXu*  Abstract  Background:  We investigated the clinicopathological characteristics and survival of breast cancer lung metastases (BCLM) patients at initial diagnosis of metastatic breast cancer (MBC) in the Han population. Methods:  We attained clinical data of 3155 MBC patients initially diagnosed between April 2000 and September 2019 from the China National Cancer Center and finally included 2263 MBC patients in this study, among which 809 patients presented with lung metastases at first MBC diagnosis. The risk factors for BCLM were determined using multivariate logistic regression analysis and the prognostic factors of BCLM patients were assessed by univariate and multivariate Cox regression analyses. Results:  Patients with triple-negative subtype (42.3%) harbored the highest incidence proportions of lung metas- tases. Age ≥ 50 years, Eastern Cooperative Oncology Group (ECOG) 2, M1, hormone receptor-negative (HR-)/human epidermal growth factor receptor 2-positive (HER2) + subtype, triple-negative subtype and disease-free survival (DFS) > 2 years were remarkably associated with higher incidence of lung metastases, while invasive lobular carci- noma (ILC) and bone metastases were significantly correlated with lower odds of lung metastases at diagnosis. The median survival of BCLM patients was 41.7 months, with triple-negative subtype experiencing the worst prognosis of 26.8 months. ECOG 2, triple-negative subtype, liver metastases, multi-metastatic sites and DFS ≤ 2 years were signifi- cantly correlated with poor survival of BCLM patients. Conclusions:  Our study provides essential information on clinicopathological features and survival outcomes of BCLM patients at initial diagnosis of MBC in China. Keywords:  Breast neoplasms, Lung, Neoplasm metastasis, Prognosis, Survival Background Lung metastasis is the second most frequent distant metastases of breast cancer [1, 2], clinically presenting*Correspondence: xubinghe@medmail.com.cn in 15–25% of metastatic breast cancer (MBC) patientsDepartment ofMedical Oncology, National Cancer Center/National [3, 4]. Autopsy data of 197 women dying with MBC overClinical Research Center forCancer/Cancer Hospital, Chinese Academy a period of 50 years revealed that 80.7% of patients hadofMedical Sciences & Peking Union Medical College, No.17, PanjiayuanNanli, Chaoyang District, Beijing100021, China lung or pleura metastases [5]. A population-based study © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/. The Creative Commons Public Domain Dedication waiver (http://​creat​iveco​ mmons.​org/​publi​cdoma​in/​zero/1.​0/) applies to the data made available in this article, unless otherwise sta ...